Functional Characterization of PPAR^-Dependent Gene Networks in Macrophages.
Functional Characterization of PPAR^-Dependent Gene Networks in Macrophages.
批准号:
8472485
负责人:
Christopher K Glass
金额:
$40.56万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-05-01 至
关键词:
2,4-thiazolidinedione3-DimensionalActinsAdipocytesAdipose tissueAnimalsAnti-Inflammatory AgentsAnti-inflammatoryCell NucleusChromatinCollaborationsComplementComplexDevelopmentDietEnvironmentEvaluationExhibitsFatty AcidsFatty acid glycerol estersFutureGene ExpressionGene TargetingGenesInflammatoryInflammatory ResponseInsulinInsulin ResistanceInterferonsInterleukin-4InvestigationLigandsLocationMacrophage ActivationMaintenanceMediatingMethodsMolecularMovementNon-Insulin-Dependent Diabetes MellitusNuclearNuclear ReceptorsObesityPathway interactionsPeroxisome Proliferator-Activated ReceptorsPhenotypePhysiologicalPlayPolyunsaturated Fatty AcidsProductionRNARegulationRepressionRoleShapesSignal PathwaySignal TransductionTLR4 geneTestingTherapeuticTherapeutic EffectTherapeutic InterventionThiazolidinedionesTissuesToll-like receptorsTranscriptbaseblood glucose regulationcytokinediabeticgenome wide association studygenome-wideimprovedin vivoinnovationinsulin sensitivitylong chain fatty acidmacrophagenovel strategiespalmitoleic acidpreventreceptorresponse
中文摘要
(附件):
项目3将研究巨噬细胞中影响胰岛素抵抗的转录网络。我们
拟议的研究将主要集中在了解意想不到的生理和细胞后果
在巨噬细胞中删除NCoR辅阻遏物,并定义分子机制,
巨噬细胞PPARy有助于正常葡萄糖稳态和胰岛素增敏作用
噻唑烷二酮类(TZDs)。这些调查将补充项目1和项目2中进行的研究。
2提高我们对驱动胰岛素发展的中枢致病机制的理解
阻力特异性目的1将检验巨噬细胞特异性NCor破坏导致
由于驱动胰岛素产生的LXR和/或PPARy靶基因的去阻遏而增强的胰岛素敏感性
抗炎脂肪酸。这些研究有可能通过以下方式确定一种全新的途径:
巨噬细胞影响胰岛素抵抗,这可能是可行的治疗干预。具体
目的2将研究巨噬细胞PPARy促进正常葡萄糖稳态的机制
和TZD的抗糖尿病作用。我们将测试的假说,基因组范围内的位置和功能,
PPARy在肥胖脂肪组织的脂肪组织巨噬细胞中受损,并通过
胰岛素致敏PPARy配体。这些研究将利用新的体内方法来确定
不需要广泛纯化的脂肪组织中巨噬细胞特异性过氧化物酶体增殖体激活受体的定位和功能
方法.具体目标3的研究将与项目2合作进行,以检验假设
巨噬细胞活化改变了染色质相互作用组,
基因表达和拮抗TLR 4依赖性基因表达。这些研究将测试一个新的概念
了解抗炎和促炎信号如何在三维水平上整合
在细胞核中。
相关性(见说明):
这些研究对提高对中枢性致病的认识具有重要意义
推动胰岛素抵抗发展和塑造未来治疗方法的机制
预防和治疗2型糖尿病。
英文摘要
instrucUons):
Project 3 will investigate transcriptional networks in macrophages that influence Insulin resistance. Our
proposed studies will primarily focus on understanding unexpected physiological and cellular consequences
of deletion of the NCoR co-repressor in macrophages and on deflning the molecular mechanisms by which
macrophage PPARy contributes to normal glucose homeostasis and insulin sensitizing effects of
thiazolidinediones (TZDs). These lines of investigation will complement studies performed in Projects 1 and
2 to improve our understanding of central pathogenic mechanisms that drive the development of insulin
resistance. Speciflc Aim 1 will test the hypothesis that macrophage-speciflc disruption of NCor results in
enhanced insulin sensitivity due to de-repression of LXR and/or PPARy target genes that drive production of
anti-inflammatory fatty acids. These studies have the potential to identify a fundamentally new pathway by
which macrophages influence insulin resistance that may be amendable to therapeutic intervention. Specific
Aim 2 will investigate mechanisms by which macrophage PPARy contributes to normal glucose homeostasis
and anti-diabetic effects of TZDs. We will test the hyothesis that the genome-wide locations and functions of
PPARy are compromised in adipose tissue macrophages of obese adipose tissue and are restored by
insulin-sensitizing PPARy ligands. These studies will make use of new in vivo approaches for determining
macrophage-specific PPAR location and function in adipose tissue that do not require extensive purification
methods. Studies in Specific Aim 3 will be performed in collaboration with Project 2 to test the hypothesis
that alternative macrophage activation alters the chromatin interactome so as to facilitate PPARy-dependent
gene expression and antagonize TLR4-dependent gene expression. These studies will test a new concept
for understanding how anti-inflammatory and pro-inflammatory signals are integrated at a 3 dimensional level
in the nucleus.
RELEVANCE (See instmctions):
The proposed studies will be of signiflcance in improving our understanding of central pathogenic
mechanisms that drive the development of insulin resistance and in shaping future therapeutic approaches
to prevent and treat type 2 diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
-
批准号:10683961
-
项目类别:
-
资助金额:$249.25万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Macrophage-specific targeting of LXRs in CVD and NASH
-
批准号:10262918
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
-
批准号:10262913
-
项目类别:
-
资助金额:$252.51万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Macrophage-specific targeting of LXRs in CVD and NASH
-
批准号:10461064
-
项目类别:
-
资助金额:$36.81万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
-
批准号:10461059
-
项目类别:
-
资助金额:$251.82万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Administrative Core
-
批准号:10683963
-
项目类别:
-
资助金额:$12.54万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Macrophage-specific targeting of LXRs in CVD and NASH
-
批准号:10683973
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Administrative Core
-
批准号:10262915
-
项目类别:
-
资助金额:$12.54万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
Administrative Core
-
批准号:10461061
-
项目类别:
-
资助金额:$12.53万
-
财政年份:2020
-
负责人:Christopher K Glass
-
依托单位:
The Enhancer Code of AD-A Genetic Approach
-
批准号:9905343
-
项目类别:
-
资助金额:$106.13万
-
财政年份:2018
-
负责人:Christopher K Glass
-
依托单位:
The Enhancer Code of AD-A Genetic Approach
-
批准号:9752405
-
项目类别:
-
资助金额:$106.08万
-
财政年份:2018
-
负责人:Christopher K Glass
-
依托单位:
The Enhancer Code of AD-A Genetic Approach
-
批准号:10399455
-
项目类别:
-
资助金额:$106.37万
-
财政年份:2018
-
负责人:Christopher K Glass
-
依托单位:
Mechanisms controlling human microglia gene expression
-
批准号:9081167
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2016
-
负责人:Christopher K Glass
-
依托单位:
Mechanisms controlling human microglia gene expression
-
批准号:9271257
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2016
-
负责人:Christopher K Glass
-
依托单位:
Mechanisms controlling human microglia gene expression
-
批准号:10495183
-
项目类别:
-
资助金额:$47.16万
-
财政年份:2016
-
负责人:Christopher K Glass
-
依托单位:
Enhancer Therapy
-
批准号:8411811
-
项目类别:
-
资助金额:$129.32万
-
财政年份:2012
-
负责人:Christopher K Glass
-
依托单位:
Enhancer Therapy
-
批准号:8921152
-
项目类别:
-
资助金额:$127.13万
-
财政年份:2012
-
负责人:Christopher K Glass
-
依托单位:
Enhancer Therapy
-
批准号:8712212
-
项目类别:
-
资助金额:$127.46万
-
财政年份:2012
-
负责人:Christopher K Glass
-
依托单位:
PROJECT 1: SPATIOTEMPORAL GENOME ARCHITECTURE
-
批准号:8957391
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2010
-
负责人:Christopher K Glass
-
依托单位:
PROJECT 1: SPATIOTEMPORAL GENOME ARCHITECTURE
-
批准号:9293325
-
项目类别:
-
资助金额:$28.72万
-
财政年份:2010
-
负责人:Christopher K Glass
-
依托单位:
海外基金